Veradigm Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 11:15 AM Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Anne Elizabeth Samuel - JPMorgan Chase & Co, Research Division - Analyst : Great. Welcome, Will. So maybe we could kick it off here with a discussion on some of the risks and perils of general purpose models in health care. So we've heard a lot about large language models. Are these a good fit in health care? William Manidis Sure. It's undeniable that chat GPT was kind of a break glass moment for industry, right? We went from having 20 years of AI promise to having a technology that is in everyone's hands that is intelligent and broadly applicable. The issue is we haven't benchmarked that technology or built in a way that is responsible for health care. The models that we serve to customers are a reflection of the data that they're trained on. And as we move from prototypes to production, to patients, it's important that we reflect on the data these models are trained on, how we deploy them in the safeguards we build. At Science, we focus on building the world's safest large language models like we used in health care. And our collaboration with Veradigm is focused around getting access to high-quality data across disparate patient populations to ensure these models can be used safely and well across industry.

Question: Anne Elizabeth Samuel - JPMorgan Chase & Co, Research Division - Analyst : And can we discuss maybe some of the pitfalls of using these as it relates to health care space. I think something that we've heard from others as they think about building out AI models and health care is hallucinations, things can appear differently than they are or there's a real problem with health equity and making sure that you're getting information across a really wide spectrum. William Manidis Sure. I would say as we move into prototype across industry, many folks are deploying generalist models and seeing very strong results because they're piloting on small patient populations that are largely homogeneous. As we move into health care broadly, and we see patients that are as diverse as the folks in this room and more, having these models be safely deployed across that context, is incredibly difficult. And being able to benchmark where the shortfalls of these models are is largely a problem that I don't think the industry has taken seriously enough, right? Hallucinations step 1, but step 2 is the bias in the underlying data, the bias and the kind of observations we make and the patients we see and the results these models put out.

Question: Anne Elizabeth Samuel - JPMorgan Chase & Co, Research Division - Analyst : And maybe another one is, how is how -- maybe both of your companies kind of positioned for the future of AI and Health Care? And also, how are you prepared to maybe close the gaps in health care for some of these underserved populations?

Question: Anne Elizabeth Samuel - JPMorgan Chase & Co, Research Division - Analyst : And maybe we could spend a little bit of time addressing some of the revenue models for Applied Healthcare AI.

Question: Anne Elizabeth Samuel - JPMorgan Chase & Co, Research Division - Analyst : You talked a little bit about -- before about kind of providers being slow moving, sometimes resistant to change. Can you maybe spend some time talking about what are the biggest hurdles to creating some of these intelligent healthcare tools. William Manidis Yes. I don't think it's provider excitement. Honestly, if you go on TikTok today and type in chat GPT doctor, you will see physicians using chat GPT for their daily practice, from submitting prior authorizations to filling out documents. Providers want this tooling. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 10, 2024 / 7:15PM, JPM.N - Veradigm Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference

Question: Anne Elizabeth Samuel - JPMorgan Chase & Co, Research Division - Analyst : And maybe just one more on AI. How do you envision the future impact of AI on health care? William Manidis I think a lot of how people have been thinking about it to date is giving kind of additional leverage to the workflows providers already do. I think that is both correct and also an understatement of the total impact that it will have. The kind of intelligence we're building with large language models are very different from the kind of intelligence that a provider might have and has different strengths and weaknesses. If we think about the population scale analytics that were previously impossible because the data wasn't ready or well-formatted enough, that something a provider could never do. No provider is going to sit there and abstract thousands of medical records by hand, but a model can do that easily. So you think about both increased efficiency, safety and cost at point of clinic, but also opening up new analytic pathways and new modalities of care that are possible by having algorithms that can do things that are not things providers can do.

Question: Anne Elizabeth Samuel - JPMorgan Chase & Co, Research Division - Analyst : I mean it's funny to think -- I mean, the EMR is such a source of friction and burden for the provider in the health care ecosystem, it's kind of an interesting perspective to maybe fix that problem.

Question: Anne Elizabeth Samuel - JPMorgan Chase & Co, Research Division - Analyst : Maybe just one more for you, Dr. Ho on just kind of Veradigm specifically. What are you most excited for as you look into 2024 now sitting in the seat where you sit?

Question: Anne Elizabeth Samuel - JPMorgan Chase & Co, Research Division - Analyst : Terrific. Well, thank you so much for joining us today, and thanks, everyone, for attending. DISCLAIMER Refinitiv reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes. In the conference calls upon which Event Briefs are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized. THE INFORMATION CONTAINED IN EVENT BRIEFS REFLECTS REFINITIV'S SUBJECTIVE CONDENSED PARAPHRASE OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT BRIEF. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 10, 2024 / 7:15PM, JPM.N - Veradigm Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference